SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer

Advanced Prostate Cancer Consensus Conference shared a post on LinkedIn about a recent paper by Antonio José Conde Moreno et al. published in ASTRO Practical Radiation Oncology.

“A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)”

Authors: Antonio José Conde Moreno, Fernando López Campos, Asunción Hervás, Virginia Morillo Macías, Jeannette Josefina Valero Albarran, Alfonso Gomez-Iturriaga, Mikel Rico, Pilar Maria Samper Ots, Luis Alberto Pérez Romasanta, Almudena Zapatero, Carlos Ferrer Albiach et al.

“A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05) out on American Society for Radiation Oncology (ASTRO) Practical Radiation Oncology.

The SBRT-Spanish Group-05 trial (NCT02192788) is a multicenter, phase II study investigating the combination of stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) in patients with oligorecurrent Prostate Cancer.

The trial included hormone-sensitive and castration-resistant cohorts, assessing oncologic outcomes and toxicity over a median follow-up of 40 months.

Results showed Excellent local recurrence-free survival rates, with 92.5% in hormone-sensitive and 85.7% in castration-resistant patients at three years.

Metastasis progression-free survival also remained high in hormone-sensitive patients but was lower in the castration-resistant group. Importantly, no grade III or higher toxicities were observed, demonstrating the safety and efficacy of SBRT and ADT in this setting.”

Source: Advanced Prostate Cancer Consensus Conference/LinkedIn